JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia

Chronic myelogenous leukemia (CML) is a hematological malignancy that highly depends on the BCR-ABL1/STAT5 signaling pathway for cell survival. First-line treatments for CML consist of tyrosine kinase inhibitors that efficiently target BCR-ABL1 activity. However, drug resistance and intolerance are...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Haidée Aranda-Tavío, Carlota Recio, Pedro Martín-Acosta, Miguel Guerra-Rodríguez, Yeray Brito-Casillas, Rosa Blanco, Vanessa Junco, Javier León, Juan Carlos Montero, Lucía Gandullo-Sánchez, Grant McNaughton-Smith, Juan Manuel Zapata, Atanasio Pandiella, Angel Amesty, Ana Estévez-Braun, Leandro Fernández-Pérez, Borja Guerra
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Chronic myelogenous leukemia BCR-ABL1 Synergism Imatinib resistance Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/92342ec5291144c1b598681c8beb4683
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia

Ejemplares similares